Dipraglurant

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Wednesday, April 3, 2024
Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points: 
  • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
  • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
  • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
  • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

Addex Provides Corporate Update and Financial Guidance

Retrieved on: 
Thursday, July 21, 2022
Speech disorder, Allosteric regulation, Glutamic acid, SIX Swiss Exchange, Nasdaq, Dipraglurant, Protein, American depositary receipt, Schizophrenia, CEO, SUD, Parkinson's disease, Research, GABA, Glutamate (neurotransmitter), Drug discovery, Partnership, Psychosis, NAM, Therapy, Lists of diseases, Janssen, Clinical trial, ADX71149, PAM, Epilepsy, Review, PTSD, LR, Patient, Janssen Pharmaceuticals, Pain, Stroke, Depression, IND, Pharmaceutical industry, Indivior

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidance.
  • We completed the half year with CHF8.8 million of cash and expect to be able to finance our operations until the end of 2022.
  • During this period, we will focus on concluding partnering agreements on selected pipeline assets to secure the financial resources to advance their development and strengthen our balance sheet, said Tim Dyer, CEO of Addex.
  • Addex is also advancing a broad preclinical pipeline, which includes GABABPAM, mGlu7NAM, mGlu2NAM, M4PAM, mGlu4PAM and mGlu3PAM.

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Retrieved on: 
Friday, May 27, 2022
SIX Swiss Exchange, Glutamic acid, Nasdaq, Population, Food, PAM, Spasms, Glutamate (neurotransmitter), Psychosis, Patient, Therapy, Blepharospasm, Clinical trial, GABAB, Epilepsy, Neurodegeneration, LR, IND, ADX71149, Glutamate receptor, PTSD, Dipraglurant, Safety, Food and Drug Administration Amendments Act of 2007, Dystonia, Dyskinesia, Lists of diseases, L-DOPA, NAM, Janssen Pharmaceuticals, Protein, Drug discovery, American depositary receipt, Allosteric regulation, CEO, Pharmaceutical industry, Medical imaging

A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.

Key Points: 
  • A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.
  • The primary objective of the study was to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
  • Addex remains committed to our allosteric modulator approach to drug discovery and development with two clinical trials currently ongoing.
  • Addex has been conducting a placebo-controlled Phase 2b/3 pivotal clinical trial of dipraglurant in PD-LID patients since June 2021.

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Retrieved on: 
Wednesday, April 13, 2022
Protein, ADX71149, Nasdaq, Clinical trial, Dipraglurant, Allosteric regulation, PTSD, Glutamate (neurotransmitter), Lists of diseases, MD, Psychosis, Dyskinesia, GABAB, Drug discovery, Dystonia, Patient, SIX Swiss Exchange, LR, PAM, Janssen Pharmaceuticals, Trial of the century, Blepharospasm, Glutamate receptor, American depositary receipt, L-DOPA, Safety, NAM, Epilepsy, Neurodegeneration, Glutamic acid, Therapy, Spasms, Pharmaceutical industry

Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.

Key Points: 
  • Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.
  • A total of 15 patients have been enrolled into this double-blind, placebo controlled Phase 2a feasibility study.
  • The primary objective of the study is to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
  • The effects on the severity and frequency of blepharospasm signs and symptoms using objective measures, clinical ratings and patient reported outcomes will also be evaluated as secondary endpoints.

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Retrieved on: 
Monday, August 2, 2021
Enzyme kinetics, Branches of biology, Organic compounds, Chemistry, Proteins, Dipraglurant, Imidazopyridines, Organofluorides, Allosteric regulation, ASD, Dystonia, Allosteric modulator

Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Key Points: 
  • Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

Retrieved on: 
Wednesday, July 7, 2021
Dipraglurant, Imidazopyridines, Organofluorides, Organ systems, Pharmacology, Dystonia, Blepharospasm, Pharmaceutical industry, Health

Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021.

Key Points: 
  • Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021.
  • Mr. Dyer will give a corporate update, including an overview of recent advances in Addexs clinical trial program.
  • To learn more about the event or to schedule a one-on-one meeting with Addex management, please visit https://www.accesstogiving.com/ or email [email protected] .
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease

Retrieved on: 
Tuesday, June 29, 2021
Neurological disorders, Organic compounds, Parkinson's disease, Branches of biology, Dipraglurant, Imidazopyridines, Organofluorides, Levodopa-induced dyskinesia, Catecholamines, Dyskinesia, L-DOPA

We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.

Key Points: 
  • We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.
  • In a Phase 2a study dipraglurant met its primary endpoint by being generally well tolerated and showing no clinically significant safety issues.
  • However, the development of dyskinesia which may be associated with long-term use of levodopa can become as disabling as the symptoms of Parkinson's disease.
  • Addexs lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) is in a pivotal registration clinical trial for Parkinsons disease levodopa induced dyskinesia (PD-LID).

Addex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia

Retrieved on: 
Monday, May 17, 2021
Dipraglurant, Imidazopyridines, Organofluorides, Dystonia, Metabotropic glutamate receptor 5, Chemistry, Branches of biology, Neuroscience

b'Geneva, Switzerland, May 17, 2021 \xe2\x80\x93 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that dipraglurant was able to rescue long-term impairment of synaptic plasticity in two well validated models of dystonia.

Key Points: 
  • b'Geneva, Switzerland, May 17, 2021 \xe2\x80\x93 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that dipraglurant was able to rescue long-term impairment of synaptic plasticity in two well validated models of dystonia.
  • Our studies evaluating the inhibition of mGlu5 receptors with dipraglurant in two etiologically distinct forms of dystonia models demonstrate that this target is now validated as a promising approach to treat dystonia,\xe2\x80\x9d said Dr Pisani.
  • \xe2\x80\x9cIn addition, the data suggest there are common mechanistic bases and signaling pathways impaired in different forms of dystonia, highlighting the potential of dipraglurant as a novel therapeutic avenue for the treatment of dystonias.
  • A placebo-controlled Phase\xc2\xa02 clinical trial of dipraglurant in blepharospasm patients is scheduled to begin during Q2 2021.

Addex Convenes Annual General Meeting 2021

Retrieved on: 
Friday, May 14, 2021
Organic compounds, Parkinson's disease, Dipraglurant, Imidazopyridines, Organofluorides, Chemical compounds, Nervous system, Neurological disorders, Dystonia, Dyskinesia, Levodopa-induced dyskinesia, L-DOPA, Organic compounds, Parkinson's disease, Dipraglurant, Imidazopyridines, Organofluorides, Chemical compounds, Nervous system, Neurological disorders, Dystonia, Dyskinesia, Levodopa-induced dyskinesia, L-DOPA

In accordance with the COVID-19 Ordinance 3, the Board of Directors ordered that all shareholders may exercise their rights at the Annual General Meeting (AGM) exclusively through the Independent Voting Rights Representative, Robert P. Briner, attorney-at-law, B & B Avocats.

Key Points: 
  • In accordance with the COVID-19 Ordinance 3, the Board of Directors ordered that all shareholders may exercise their rights at the Annual General Meeting (AGM) exclusively through the Independent Voting Rights Representative, Robert P. Briner, attorney-at-law, B & B Avocats.
  • Addex\xe2\x80\x99s lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson\xe2\x80\x99s disease levodopa induced dyskinesia (PD-LID) in Q2 2021.
  • Addex is also investigating dipraglurant\'s therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q2 2021.
  • Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.\n'

Addex Reports Q1 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 5, 2021
Organic compounds, Dipraglurant, Imidazopyridines, Organofluorides, Branches of biology, Organ systems, Enzyme kinetics, Dystonia, Blepharospasm, Allosteric regulation, Indivior, Addiction

Research and development expenses consist primarily of costs associated with research, preclinical and clinical testing, and related staff costs.

Key Points: 
  • Research and development expenses consist primarily of costs associated with research, preclinical and clinical testing, and related staff costs.
  • Addex\xe2\x80\x99s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex is also investigating dipraglurant\'s therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q2 2021.
  • Addex\xe2\x80\x99s GABAB PAM program has been licensed to Indivior PLC, which is focused on development for the treatment of addiction.